• Gene One Life Science postponed payment for its KRW 15 billion private placement to Nov. 26, 2026, from Oct. 23.
• Revolt Investment Partnership requested the delay to review the company's legal response to a US default judgment involving Inovio.
• The company is seeking to vacate the judgment on procedural and substantive grounds.
• New-share delivery and listing were rescheduled to Dec. 10, 2026, from Nov. 6.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261023000364), on October 23, 2026, and is solely responsible for the information contained therein.